Most Recent
The successor of Dow Agrosciences has lost its latest bid to register a patent that is aimed at limiting the worldwide problem of herbicide vapour drift after a delegate found that its seventh such patent had no inventive step.
Seven Network has appealed a ruling that revoked its 7NOW trade mark for non-use in a victory for convenience chain 7-Eleven as it seeks to expand its presence in Australia.
Seven Network has lost its effort to stop convenience chain 7-Eleven from using a contested logo even though Seven had registered the trade mark first, with a court finding the broadcaster sat on the mark for too long before using it.
Big Six firm King & Wood Mallesons has withdrawn its representation of US rapper Ye in his case against a small Melbourne restaurant after the artist reportedly failed to instruct his lawyers.
Sportsbet has won an injunction preventing the owner of the sportsbet.com domain from prosecuting an action in the US, which a judge said sought to interfere with an Australian domain name battle “in the most stark fashion.”
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
Nufarm Australia has successfully challenged a herbicide patent application by Dow Agrosciences’ successor on the grounds that the invention – aimed at limiting the worldwide problem of vapor drift – is neither new nor innovative.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim's appeal of ruling that shot down its opposition to Merck Sharp & Dohme's patent application for an injectable anti-parasite drug for livestock.
The Federal Court has signed off on a settlement between two US biotech companies that ends a dispute over the companies' 'Access' trade marks in Australia.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.